Health CarePharmaceuticals & Biotechnology
  • Price (USD)83.87
  • Today's Change-1.61 / -1.88%
  • Shares traded4.23m
  • 1 Year change19.90%
  • Beta1.1124
Data delayed at least 15 minutes, as of Dec 09 2019 23:30 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

  • Revenue in USD (TTM)31.36bn
  • Net income in USD3.29bn
  • Incorporated1900
  • Employees103.00k
  • Location
    Abbott Laboratories100 Abbott Park RdABBOTT PARK 60064-3500United StatesUSA
  • Phone+1 (224) 667-6100
  • Websitehttp://www.abbott.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ABT:NYQ since
GLP Systems GmbHDeal completed27 Jun 201927 Jun 2019Deal completed1.10%147.78m
Data delayed at least 15 minutes, as of Dec 09 2019 23:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Zimmer Biomet Holdings Inc7.93bn-81.90m30.55bn19.00k--2.5333.103.85-0.4475-0.488238.5358.760.3190.94956.57417,236.80-0.33851.26-0.38651.3972.5670.96-1.063.930.54034.910.408566.571.6611.40-168.51--8.433.71
Baxter International Inc11.08bn1.39bn42.46bn50.00k31.835.4319.483.832.612.9720.8415.310.64943.766.04221,600.008.148.539.6210.8642.6542.2812.5416.272.1043.420.397132.915.363.408.7135.20-14.89-17.59
Edwards Lifesciences Corp4.15bn819.70m49.84bn12.80k61.8513.0655.0812.013.863.6519.5718.300.69631.788.36324,343.8013.7516.0316.5819.0774.4074.1919.7423.372.74--0.13480.008.3712.72-15.9213.6617.03--
Boston Scientific Corporation10.39bn1.03bn61.44bn32.00k60.156.3330.755.910.73290.77417.386.960.4412.266.16324,750.004.382.815.463.5070.6970.489.936.080.77133.400.52890.008.576.5866.22--11.05--
Intuitive Surgical, Inc.4.25bn1.29bn67.68bn5.53k54.348.7246.0315.9310.7811.0135.5767.140.51642.736.97768,463.9015.6014.2817.3415.9769.4568.8030.2027.414.01--0.000.0018.6710.4614.1310.9612.37--
Becton Dickinson and Co17.29bn1.03bn70.51bn70.09k69.383.3421.484.083.763.9463.2177.950.32723.587.41246,658.002.242.792.553.2247.9347.276.847.200.72244.760.479172.798.1815.4129.16-2.737.947.16
Stryker Corporation14.55bn1.87bn76.37bn36.00k41.506.2029.085.254.929.0238.3132.900.5971.626.45404,138.907.667.639.189.3965.7066.2412.8313.071.35--0.405939.869.308.567.6114.6624.0112.14
Thermo Fisher Scientific Inc.25.22bn3.56bn128.37bn70.00k36.324.3722.065.098.818.8962.4373.210.45114.456.12360,285.706.374.947.075.5844.4845.0914.1211.691.238.550.367510.8016.4513.2225.6219.0221.831.92
Abbott Laboratories31.36bn3.29bn151.17bn103.00k46.214.7523.954.821.851.8517.6317.990.44743.175.85304,417.504.703.635.654.3758.6456.3910.508.
Medtronic PLC30.89bn4.62bn151.58bn90.07k33.083.0020.704.913.423.4522.8537.730.34482.405.21342,962.805.194.395.734.9069.6369.2615.0714.552.2810.950.335754.462.0212.44-13.808.6623.4212.30
Data as of Dec 09 2019. Currency figures normalised to Abbott Laboratories's reporting currency: US Dollar USD

Institutional shareholders

34.74%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2019147.54m8.35%
Capital Research & Management Co. (Global Investors)as of 30 Sep 2019113.07m6.40%
BlackRock Fund Advisorsas of 30 Sep 201986.15m4.88%
SSgA Funds Management, Inc.as of 30 Sep 201972.58m4.11%
Capital Research & Management Co. (International Investors)as of 30 Sep 201946.00m2.60%
Wellington Management Co. LLPas of 30 Sep 201940.69m2.30%
Massachusetts Financial Services Co.as of 30 Sep 201931.89m1.80%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 201926.27m1.49%
Fidelity Management & Research Co.as of 30 Sep 201925.04m1.42%
Geode Capital Management LLCas of 30 Sep 201924.67m1.40%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.